

CLEARBRIDGE HEALTH LIMITED

(Company Registration No.: 201001436C)

(Incorporated in the Republic of Singapore)

FURTHER EXTENSION OF CONVERTIBLE BOND MATURITY DATE

Unless otherwise defined, capitalised terms used herein shall bear the same meanings ascribed to them in the Company's announcements dated 7 October 2022, 15 December 2022 and 6 October 2025 in relation to the Bonds ("**Announcements**").

1. **AMENDMENT DEED TO TERMS AND CONDITIONS OF CONVERTIBLE BONDS**

The Board wishes to announce that further to the Amendment Deed, CBH and RDH have today each entered into an amendment deed (the "**Second Amendment Deed**") with the Issuer to extend the Maturity Date of the Bonds from four (4) years to five (5) years from the date of issue of the Bonds (the "**Extension**"). Accordingly, the Maturity Date of the Bonds shall be extended from 7 October 2026 to 7 October 2027. Save for the above, the conditions of the Bonds remain substantially unchanged.

2. **INTEREST OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS**

None of the Directors and their respective associates, and to the best of the knowledge of the Directors, none of the substantial shareholders of the Company and their respective associates, has any interest, direct or indirect, in the Extension, other than through their respective directorship and shareholdings in the Company, if any.

3. **RATIONALE FOR THE EXTENSION**

Based on representations from the Issuer, the Board notes that whilst the Issuer faces continuing challenges in exercising control over the IGM Labs and TMJ (entities disposed under the Disposal), it is in the midst of engaging in legal proceedings for the same. Further, the Issuer has represented that in accordance with terms of the Bonds, at this stage, it is required to effect a Mandatory Conversion of the Bonds on its maturity date.

Taking into consideration the above, the Board is of the view that the better position is for the Issuer to continue to manage the affairs of IGM Labs and TMJ, including the legal proceedings, in view of their business being based in Indonesia. In light thereof, the Board is of the view that it would be more effective for the Group to decide on the exercise of its rights under the Bonds when there is more certainty on the outcome of the Issuer's control over IGM Labs and TMJ.

4. **DOCUMENTS AVAILABLE FOR INSPECTION**

Copies of the Second Amendment Deed is available for inspection during normal business hours at the registered office of the Company at 37 Jalan Pemimpin, #08-05, Mapex, Singapore 577177 for a period of three (3) months from the date of this announcement.

By Order of the Board

Ong Choon Yi (Wang Junyi)
Executive Director and Group Chief Executive Officer

6 October 2026

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.